Neuropilin-2 in Alloimmunity
同种免疫中的 Neuropilin-2
基本信息
- 批准号:10355442
- 负责人:
- 金额:$ 50.9万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-03-01 至 2025-02-28
- 项目状态:未结题
- 来源:
- 关键词:1-Phosphatidylinositol 3-KinaseAcuteAddressAllograftingAntigensAreaBindingBiologicalBiological ProcessBiological Response Modifier TherapyBiologyBostonCD4 Positive T LymphocytesCell Differentiation processCell physiologyCell surfaceCellsCellular Metabolic ProcessChronicCollaborationsDevelopmentFOXP3 geneFRAP1 geneFamilyFutureGlycoproteinsGraft RejectionGraft SurvivalGrowthHomeostasisHumanImmuneImmune responseImmunityImmunosuppressionIn VitroIndividualKnock-outKnockout MiceLeadLifeLigandsLinkLiteratureMalignant NeoplasmsMediatingMediator of activation proteinMetabolic PathwayMinorModelingMolecularMusNeuropilin-1Neuropilin-2NeuropilinsOrgan TransplantationOutcomePathway interactionsPediatric HospitalsPharmacologyPreventionProcessRegulationRegulatory T-LymphocyteReportingResearchResearch ProposalsResolutionRoleSEMA3F geneSavingsSemaphorinsSignal TransductionT-Cell ActivationT-LymphocyteT-Lymphocyte SubsetsTestingTherapeuticTransplantationallograft rejectionangiogenesisaxon guidancecell growthcell typeclinically relevantcohesionend-stage organ failureheart allograftimmune functionimmunoregulationin vivoinhibitorinnovationinsightinterestisoimmunitymigrationnovelplexinpost-transplantpreventreceptorresponseselective expressiontherapeutic developmenttumor initiationtumor progression
项目摘要
Project Summary/Abstract
Allograft rejection is characterized by effector CD4+ T cell activation in response to donor antigen and an
intense cellular and humoral attack on the graft. However, multiple intracellular signals within CD4+ T cells
operate co-incidentally to control and regulate effector alloimmunity, and it is proposed that this process of
immunoregulation is a vital and perhaps more potent component of the response. The neuropilin (NRP)
receptors, NRP-1 and NRP-2, are single spanning transmembrane glycoproteins that were initially
discovered as chemorepulsive mediators of axonal guidance. However, they are now recognized to function
in a wide range of important biological processes including migration, angiogenesis, and cell growth. In
addition, they have recently been shown to have pluripotent functions in the immune response as well as in
tumor initiation and progression. Over the past decade, several groups have identified critical functions for
NRP-1 in immunity, notably related to its expression on induced Tregulatory cells where it functions to
augment immunoregulation. In contrast, much less is known about the immunological function of NRP-2
and it has only recently been demonstrated to be expressed on immune cells. In preliminary studies, we find
that NRP-2 is expressed on subsets of both human and murine CD4+ effector and regulatory cells.
Furthermore, we find that Semaphorin3F, a well established ligand for NRP-2, is potent to inhibit PI-3K
activity as well as mTOR signaling that are reported to modulate CD4+ T cell activation. Also, we find that
CD4+ T cells from NRP-2 knockout mice mount enhanced effector responses following activation in vitro
and in vivo. These observations have shaped a working model whereby the induced expression of NRP-2
on CD4+ T cells functions to modulate activation, and they suggest that its biological effects have
consequences for the outcome of the alloimmune response. Our objectives in this R01 are to: 1), identify
how NRP-2 modulates regulatory signaling responses and cell metabolism in CD4+ subsets, 2), evaluate
whether Semaphorin3F serves to regulate CD4+ T cell activation responses, and 3), evaluate whether
Sema3F-NRP-2 interactions can be exploited in vivo to augment immunoregulation post transplantation
and/or to induce Teffector responses that limit cancer growth. We will test the hypothesis that CD4+ T cell
NRP-2 interacts with Semaphorin3F and/or additional ligands to modulate Teffector cell activation and to
augment Tregulatory cell function and immunoregulation following transplantation. We propose two specific
aims in which we will: 1), identify the mechanism of NRP-2-induced regulatory signaling and the
consequences of NRP-2 loss in CD4+ T cell subsets, and 2), determine the function of CD4+ T cell NRP-2 in
the prevention of rejection and in long-term allograft survival. Collectively, these innovative studies will have
broad scientific and biological implications of great significance and relevance in immunity.
项目摘要/摘要
同种异体移植排斥的特征是效应子CD4+ T细胞激活供体抗原和A
对移植物的强烈细胞和体液攻击。但是,CD4+ T细胞中的多个细胞内信号
共同运行以控制和调节效应子同种异体,并提议此过程
免疫调节是反应的重要组成部分。 Neuropilin(NRP)
受体NRP-1和NRP-2是单个跨膜糖蛋白,最初是
被发现为轴突引导的化学螺栓介质。但是,他们现在被认为功能
在广泛的重要生物学过程中,包括迁移,血管生成和细胞生长。在
此外,最近已显示它们在免疫反应中具有多能功能
肿瘤的启动和进展。在过去的十年中,几个小组确定了关键功能
NRP-1的免疫力,特别与其在诱导的Tregulatory细胞上的表达有关,在该细胞中起作用
增强免疫调节。相比之下,关于NRP-2的免疫功能知之甚少
直到最近才证明它是在免疫细胞上表达的。在初步研究中,我们发现
NRP-2在人和鼠CD4+效应子和调节细胞的子集上表达。
此外,我们发现Semaphorin3F是NRP-2的良好配体,有效抑制PI-3K
据报道调节CD4+ T细胞激活的活性以及MTOR信号传导。另外,我们发现
NRP-2基因敲除小鼠的CD4+ T细胞在体外激活后增强效应子响应
和体内。这些观察结果已塑造了一个工作模型,该模型诱导了NRP-2的表达
关于CD4+ T细胞的作用以调节激活,它们表明其生物学作用具有
同种免疫反应结果的后果。我们在此R01中的目标是:1),确定
NRP-2如何调节CD4+子集中的调节信号反应和细胞代谢,2)
Semaphorin3F是否用于调节CD4+ T细胞激活反应,3)是否评估是否是否
可以在体内利用SEMA3F-NRP-2相互作用,以增加移植后免疫调节
和/或诱导限制癌症生长的Teffector反应。我们将测试CD4+ T细胞的假设
NRP-2与Semaphorin3F和/或其他配体相互作用,以调节Teffector细胞激活和TO
移植后增强TREGULATION细胞功能和免疫调节。我们提出了两个特定的
我们将要:1)确定NRP-2诱导的调节信号的机制和
CD4+ T细胞子集中NRP-2损失的后果,2)确定CD4+ T细胞NRP-2在中的功能
预防排斥和长期同种移植生存。总的来说,这些创新研究将有
具有巨大意义和相关性的广泛科学和生物学意义。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
David M. Briscoe其他文献
Outcome of renal transplantation in children less than two years of age
- DOI:
10.1038/ki.1992.331 - 发表时间:
1992-09-01 - 期刊:
- 影响因子:
- 作者:
David M. Briscoe;Melanie S. Kim;Craig Lillehei;Angelo J. Eraklis;Raphael H. Levey;William E. Harmon - 通讯作者:
William E. Harmon
Risk factors for mortality in infants and young children on dialysis.
透析婴幼儿死亡的危险因素。
- DOI:
- 发表时间:
2001 - 期刊:
- 影响因子:13.2
- 作者:
Ellen G. Wood;Matthew Hand;David M. Briscoe;Lynn A. Donaldson;Verna Yiu;Frances L. Harley;B. Warady;Eileen N. Ellis - 通讯作者:
Eileen N. Ellis
David M. Briscoe的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('David M. Briscoe', 18)}}的其他基金
Role of DEPTOR in T Cell Activation and Alloimmunity
DEPTOR 在 T 细胞激活和同种免疫中的作用
- 批准号:
10062851 - 财政年份:2017
- 资助金额:
$ 50.9万 - 项目类别:
Role of DEPTOR in T Cell Activation and Alloimmunity
DEPTOR 在 T 细胞激活和同种免疫中的作用
- 批准号:
10302288 - 财政年份:2017
- 资助金额:
$ 50.9万 - 项目类别:
Function of DepTOR in T Cell Activation and Alloimmunity
DepTOR 在 T 细胞激活和同种免疫中的作用
- 批准号:
8785808 - 财政年份:2014
- 资助金额:
$ 50.9万 - 项目类别:
Vascular Endothelial Growth Factor Receptor Interactions and Allograft Rejection
血管内皮生长因子受体相互作用和同种异体移植排斥
- 批准号:
8239118 - 财政年份:2011
- 资助金额:
$ 50.9万 - 项目类别:
Role of T cell Specific Adaptor Protein in Alloimmunity
T 细胞特异性衔接蛋白在同种免疫中的作用
- 批准号:
8190975 - 财政年份:2011
- 资助金额:
$ 50.9万 - 项目类别:
相似国自然基金
阿魏酸基天然抗氧化抗炎纳米药物用于急性肾损伤诊疗一体化研究
- 批准号:82302281
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
SGO2/MAD2互作调控肝祖细胞的细胞周期再进入影响急性肝衰竭肝再生的机制研究
- 批准号:82300697
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于hemin-MOFs的急性心肌梗塞标志物负背景光电化学-比色双模分析
- 批准号:22304039
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
RNA甲基转移酶NSUN2介导SCD1 mRNA m5C修饰调控急性髓系白血病细胞铁死亡的机制研究
- 批准号:82300173
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于IRF5/MYD88信号通路调控巨噬细胞M1极化探讨针刀刺营治疗急性扁桃体炎的机制研究
- 批准号:82360957
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:地区科学基金项目
相似海外基金
Phosphatidylinositol 3-Phosphate in the Regulation of Autophagic Membrane Remodeling
磷脂酰肌醇 3-磷酸在自噬膜重塑调节中的作用
- 批准号:
10506784 - 财政年份:2022
- 资助金额:
$ 50.9万 - 项目类别:
Novel use of PI3K inhibition to prevent recurrence of B-cell acute lymphoblastic leukemia
PI3K 抑制预防 B 细胞急性淋巴细胞白血病复发的新用途
- 批准号:
10455633 - 财政年份:2021
- 资助金额:
$ 50.9万 - 项目类别:
Novel use of PI3K inhibition to prevent recurrence of B-cell acute lymphoblastic leukemia
PI3K 抑制预防 B 细胞急性淋巴细胞白血病复发的新用途
- 批准号:
10289183 - 财政年份:2021
- 资助金额:
$ 50.9万 - 项目类别:
The Na/K-ATPase receptor function as a novel therapeutic target in myocardial infarction
Na/K-ATP酶受体作为心肌梗死的新型治疗靶点
- 批准号:
9813314 - 财政年份:2019
- 资助金额:
$ 50.9万 - 项目类别:
Acutely Induced Insulin Resistance by Antipsychotic Medication in Healthy Volunteers: Impact of Skeletal Muscle Epigenomic and Proteomic Mechanisms
健康志愿者抗精神病药物急性诱导胰岛素抵抗:骨骼肌表观基因组和蛋白质组机制的影响
- 批准号:
10220957 - 财政年份:2018
- 资助金额:
$ 50.9万 - 项目类别: